Trial Profile
Evaluation of Adherence Rate in Patients Receiving PegIntron Pen / Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 16 Sep 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 16 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2009 Planned end date changed from 1 Apr 2009 to 1 Jun 2009 as reported by ClinicalTrials.gov.